Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/28184
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mutnick, A. | - |
dc.contributor.author | Biedenbach, D. | - |
dc.contributor.author | Turnidge, J. | - |
dc.contributor.author | Jones, R. | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | Diagnostic Microbiology and Infectious Disease, 2002; 43(1):65-73 | - |
dc.identifier.issn | 0732-8893 | - |
dc.identifier.issn | 1879-0070 | - |
dc.identifier.uri | http://hdl.handle.net/2440/28184 | - |
dc.description | Copyright © 2002 Elsevier Science Inc. All rights reserved. | - |
dc.description.abstract | Resistance (R) among Gram-positive cocci has escalated in the last two decades to levels necessitating the development and use in the newer drug classes, oxazolidinones (linezolid) and streptogramins (quinupristin/dalfopristin [Q/D]). The SENTRY Antimicrobial Surveillance Program has monitored these classes before, during and after their release by various regulatory agencies. Over 30,000 Gram-positive strains were tested against >30 drugs by reference broth microdilution methods between 1998-2000 in four geographic regions (Asia-Western Pacific [APAC], Europe [EU], Latin America [LA], North America [NA]). The tested strains were 23,188 staphylococci; 5,103 enterococci and 2,045 streptococci. Among staphylococci, linezolid was active against all isolates (MICs, < or =4 microg/ml) regardless of susceptibility patterns of other antimicrobial agents. Similar results were noted for vancomycin (includes one VISA from Hong Kong), teicoplanin, and Q/D (<1% R). Gatifloxacin had the widest spectrum among fluoroquinolones (FQ) against Staphylococcus aureus (1.5-9.2% R) and coagulase-negative staphylococci (0.8-4.0%). Linezolid was also active against all enterococci (MIC50 and (90,) 2 microg/ml). Q/D was active against only 75.3% of vancomycin-resistant enterococci (VRE). The VRE rate was highest in NA (12.4%) > EU (3.2%) > LA (1.6%) > APAC (1.3%). Among streptococci, linezolid was consistently active (MIC(90,) 1 microg/ml) as were the glycopeptides and Q/D. Variable penicillin-R (MIC, > or = 2 microg/ml) was observed among regions: EU (32.5%) > APAC (15.1%) > LA (13.8%) > NA (9.6%), and macrolide-R was higher in EU (40.3%). Ciprofloxacin-R at > or =4 microg/ml in streptococcal strains was noted world wide highest in viridans group streptococci (18.4-25.6%). Linezolid remained active (MIC, < or =4 microg/ml) against all Gram-positive species strains tested in the SENTRY Program (1998-2000). Q/D, glycopeptides and newer FQ compounds were generally less effective in vitro. It remains a prudent practice to continue surveillance programs to detect emerging resistance patterns and recognize significant regional variations in the oxazolidinone susceptibilities. | - |
dc.description.statementofresponsibility | Alan H. Mutnick, Douglas J. Biedenbach, John D. Turnidge and Ronald N. Jones | - |
dc.description.uri | http://www.elsevier.com/wps/find/journaldescription.cws_home/505759/description#description | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Science Inc | - |
dc.source.uri | http://dx.doi.org/10.1016/s0732-8893(02)00371-1 | - |
dc.subject | Humans | - |
dc.subject | Gram-Negative Bacteria | - |
dc.subject | Gram-Positive Bacteria | - |
dc.subject | Acetamides | - |
dc.subject | Oxazolidinones | - |
dc.subject | Anti-Bacterial Agents | - |
dc.subject | Microbial Sensitivity Tests | - |
dc.subject | Drug Resistance, Bacterial | - |
dc.subject | Cell Division | - |
dc.subject | Substrate Specificity | - |
dc.subject | Time Factors | - |
dc.subject | Americas | - |
dc.subject | Asia | - |
dc.subject | Europe | - |
dc.subject | Linezolid | - |
dc.title | Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000 | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/S0732-8893(02)00371-1 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Turnidge, J. [0000-0003-4240-5578] | - |
Appears in Collections: | Aurora harvest 6 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.